Talon Therapeutics, Inc. (TLON.OB) is a publicly traded company in the Unknown sector. Across all available filings, 6 corporate insiders have executed 196 transactions totaling $7.4M, demonstrating a bearish sentiment with -$7.4M in net insider flow. The most recent transaction on Jul 16, 2013 involved a transaction of 4,545,880 shares valued at $1.4M.
No significant insider buying has been recorded for TLON.OB in the recent period.
No significant insider selling has been recorded for TLON.OB in the recent period.
Based on recent SEC filings, insider sentiment for TLON.OB is bearish with an Insider Alignment Score of 0/100 and a net flow of -$7.4M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Talon Therapeutics, Inc. (TLON.OB) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 6 insiders are actively trading TLON.OB stock, having executed 196 transactions in the past 90 days. The most active insider is James E. Flynn (Executive), who has made 56 transactions totaling $14.0M.
Get notified when executives and directors at TLON.OB file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jul 16, 2013 | E. Flynn James | Executive | Conversion | 4,545,880 | $0.30 | $1.4M | Large |
| Jul 16, 2013 | E. Flynn James | Executive | Conversion | 2,305,753 | $0.74 | $1.7M | Large |
| Jul 16, 2013 | E. Flynn James | Executive | Sale | 2,974,566 | $0.06 | $178.5K | |
| Jul 16, 2013 | E. Flynn James | Executive | Conversion | 592,613 | $0.35 | $207.4K | |
| Jul 16, 2013 | E. Flynn James | Executive | Conversion | 424,798 | $0.74 | $314.4K | |
| Jul 16, 2013 | E. Flynn James | Executive | Conversion | 837,215 | $0.30 | $251.2K | |
| Jul 16, 2013 | E. Flynn James | Executive | Conversion | 322,911 | $0.35 | $113.0K | |
| Jul 16, 2013 | E. Flynn James | Executive | Sale | 1,619,176 | $0.06 | $97.2K | |
| Jul 16, 2013 | E. Flynn James | Executive | Conversion | 778,856 | $0.74 | $576.4K | Large |
| Jul 16, 2013 | E. Flynn James | Executive | Sale | 14,005,557 | $0.06 | $840.3K | Large |
| Jul 16, 2013 | E. Flynn James | Executive | Conversion | 1,535,573 | $0.30 | $460.7K | |
| Jul 16, 2013 | E. Flynn James | Executive | Conversion | 2,830,978 | $0.35 | $990.8K | Large |
| Jul 16, 2013 | E. Flynn James | Executive | Conversion | 7,323,275 | $0.30 | $2.2M | Large |
| Jul 16, 2013 | E. Flynn James | Executive | Conversion | 3,714,455 | $0.74 | $2.7M | Large |
| Jul 16, 2013 | E. Flynn James | Executive | Sale | 8,694,231 | $0.06 | $521.7K | Large |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Conversion(C) | 12 | $11.5M | 61.1% |
Sale(S) | 184 | $7.4M | 38.9% |
Insider selling pressure at Talon Therapeutics, Inc. has increased, with 6 insiders executing 196 transactions across all time. Total sales of $7.4M significantly outpace purchases of $0, resulting in a net outflow of $7.4M. This selling activity appears largely discretionary, which may warrant closer attention from investors.